Live Webinar :Device Warning Letters - Review

01:00 PM EDT | 10:00 AM PDT | 12:00 PM CDT Duration 60 Minute

Webinar Includes : All the training handouts , Certificate by the Speaker ,Q/A and 60 Min Live Webinar

"Hear By Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting "

Learn the FDA process for issuance of warning letters

Description

This webinar will teach you the purpose and process of FDA issuance of warning letters.  Device warning letters issued during the last 5 years, including common deficiencies will be reviewed.

Why You should Attend The Session 

Learn the FDA process for issuance of warning letters.  Review primary deficiencies noted in warning letters for device products for the last 5 years.

 

Areas Covered

• Warning letter process

• Timing of issuance of a warning letter

• Common deficiencies cited in warning letters 

• Learnings from noted deficiencies to bring back to your organization

Who will Benefit

Manufacturing

supply chain

Technical operations

Quality control

Quality assurance

Regulatory affairs

Industries who can attend

This 60-minute online course is intended for professionals in the Medical Device, Biotechnology,Pharmaceutical Industry. Although not presently stated in the draft , the same guide could be used by FDA Regulated Industries personnel.


Speaker Profile

Peggy J. Berry.

MBA, RAC,President & CEO, Synergy Consulting (Ex-FDA Official)

Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2015, she was Vice President of Regulatory Affairs at Insmed (2/2015-5/2015) where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. Prior to Insmed, she was Vice President of Regulatory Affairs and Quality at Amarin (3/2009-2/2014). She has also held a variety of senior level positions at Dyax (5/2006-3/2009), MGI Pharma (now Eisai; 7/2005-5/2006), AstraZeneca (10/2001-7/2005), and Dey Pharma (now Mylan; 12/1997-10/2001). She has also held Regulatory Affairs roles within two clinical contract research organizations (ILEX Oncology and Cato Research Ltd; 1992-1997) and has worked in review divisions at the FDA (1985-1992). In addition, Ms. Berry consults for a number of companies in the regulatory and quality area, conducts a number of training courses, and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book "Choosing the Right Regulatory Career" (RAPS, MD) and author of the 2011 book "Communication & Negotiation" (RAPS, MD).

Back to Top